Opinion on Company Issues in North America

Published within

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Anheuser-Busch: thriving while rivals struggle

Published By Datamonitor
06 Sep 2001
ResearchWire
ResearchWire

Annuity sales: brokerages evening out the playing field

Published By Datamonitor
05 Jul 2001
ResearchWire
ResearchWire

Anthrax vaccine in bananas: will there be a market?

Published By Datamonitor
22 Oct 2001
CommentWire
CommentWire

Anti-inflammatories: Cox-IIs may not live up to the hype

Bextra is aimed at addressing the cardiovascular and kidney complications associated with its predecessors Celebrex and Vioxx. But although Cox-II inhibitors have improved toxicities compared to older NSAIDS, recent studies into the physiological functions of Cox-II should caution physicians from uncritical use of these new drugs.

Published By Datamonitor
27 Nov 2001
CommentWire
CommentWire

Anti-spam software: pure-play vendors at a disadvantage

The three major anti-virus software vendors are all building on their anti-spam offerings. Symantec, Trend Micro and Network Associates are all fighting for a share of the growing market. With these established players making moves, pure-play spam filter vendors will have a hard time gaining much market share without being acquired.

Published By Datamonitor
26 Mar 2003
CommentWire
CommentWire

Antibiotics: US doctors cut use in 1990s

US doctors cut back on unnecessary prescriptions for antibiotics in the 1990s, an encouraging finding that suggests that campaigns to curb overuse of antibiotics seem to be successful. However, when doctors do choose a drug, they are now more likely to use more broad-spectrum antibiotics, which could prove problematic in the future.

Published By Datamonitor
01 Apr 2003
ResearchWire
ResearchWire

Anticonvulsants: 12% usage rate for US migraine prophylaxis

Published By Datamonitor
12 Dec 2001
ResearchWire
ResearchWire

Antidepressants: noradrenergics sales to rise

Published By Datamonitor
15 Mar 2001
ResearchWire
ResearchWire

Antimetabolites: market will be worth $1.9 billion in 2007

Published By Datamonitor
12 Jun 2001
ResearchWire
ResearchWire

Antipsychotics: a third of R&D is taking place in the US

Published By Datamonitor
08 Jan 2002

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | ... | » »|

No help is available.